MX2020008062A - Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio. - Google Patents

Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.

Info

Publication number
MX2020008062A
MX2020008062A MX2020008062A MX2020008062A MX2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A
Authority
MX
Mexico
Prior art keywords
nucleic acid
antibodies
acid constructs
use against
against respiratory
Prior art date
Application number
MX2020008062A
Other languages
English (en)
Inventor
David Weiner
Trevor Smith
Katherine Schultheis
Jing Chen
Kar Muthumani
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2020008062A publication Critical patent/MX2020008062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente descripción se describe una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo para un antígeno del Virus Sincicial Respiratorio; también se describe en la presente descripción un método para generar un anticuerpo sintético en un sujeto mediante la administración de la composición al sujeto; la descripción también proporciona un método para prevenir y/o tratar una infección por el virus Sincicial Respiratorio en un sujeto mediante el uso de dicha composición y método de generación.
MX2020008062A 2018-01-31 2019-01-31 Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio. MX2020008062A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624320P 2018-01-31 2018-01-31
US201862749580P 2018-10-23 2018-10-23
PCT/US2019/015975 WO2019152600A1 (en) 2018-01-31 2019-01-31 Nucleic acid antibody constructs for use against respiratory syncytial virus

Publications (1)

Publication Number Publication Date
MX2020008062A true MX2020008062A (es) 2020-12-03

Family

ID=67478343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008062A MX2020008062A (es) 2018-01-31 2019-01-31 Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.

Country Status (11)

Country Link
US (1) US12617841B2 (es)
EP (1) EP3746474A4 (es)
JP (1) JP2021512600A (es)
KR (1) KR20200140799A (es)
CN (1) CN111936513A (es)
AU (1) AU2019215006A1 (es)
BR (1) BR112020015588A2 (es)
CA (1) CA3089717A1 (es)
MX (1) MX2020008062A (es)
SG (1) SG11202007241WA (es)
WO (1) WO2019152600A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194291T1 (de) * 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
US6261787B1 (en) 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US20050004055A1 (en) * 2001-11-26 2005-01-06 Elena Fattori Increasing electro-gene transfer of nucleic acid molecules into host tissue
GB0306618D0 (en) 2003-03-22 2003-04-30 Univ Newcastle Antibody
JP2012518404A (ja) 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Ｃｄ１９に結合するヒト化抗体及びその使用
CN102655853B (zh) * 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2591000B1 (en) * 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
KR20230156146A (ko) 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
KR102188437B1 (ko) * 2014-01-15 2020-12-08 메디뮨 엘엘씨 Rsv 특이적 항체 및 이의 기능적 부위
US20180237502A1 (en) 2015-03-11 2018-08-23 Integrated Biotherapeutics, Inc. Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
TWI614264B (zh) * 2015-05-20 2018-02-11 免疫功坊股份有限公司 含胜肽核的多臂接合物及其應用
ES2911015T3 (es) 2015-08-31 2022-05-17 Helixmith Co Ltd Receptores quiméricos de antígeno anti-sialil Tn
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EA201892525A1 (ru) * 2016-05-05 2019-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Конструкции днк-антител для применения против pseudomonas aeruginosa
CN120366326A (zh) 2016-05-05 2025-07-25 宾夕法尼亚大学理事会 靶向检查点分子的dna单克隆抗体

Also Published As

Publication number Publication date
EP3746474A4 (en) 2021-12-15
EP3746474A1 (en) 2020-12-09
US12617841B2 (en) 2026-05-05
CA3089717A1 (en) 2019-08-08
BR112020015588A2 (pt) 2021-01-05
JP2021512600A (ja) 2021-05-20
US20210047390A1 (en) 2021-02-18
SG11202007241WA (en) 2020-08-28
KR20200140799A (ko) 2020-12-16
AU2019215006A1 (en) 2020-09-17
WO2019152600A1 (en) 2019-08-08
CN111936513A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CL2022001375A1 (es) Receptores de antígeno quimérico cd19 y cd22 y usos de los mismos
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
MX2016016533A (es) Combinaciones inmunogenas.
MX2018014573A (es) Vacuna contra el virus del zika.
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
PE20231376A1 (es) Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2022002963A (es) Composiciones y metodos para tratar nefritis lupica.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
CL2019003393A1 (es) Virus oncolíticos y método.
PE20211295A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
MX2018013172A (es) Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13.
AR116878A1 (es) Vacuna de ibv h52 con proteína espicular heteróloga
EA202090587A1 (ru) Способ получения сплит-вакцины с на гриппа
MX2020007772A (es) Anticuerpos humanos contra hemaglutinina de influenza.